Cerebrolysin

Also known as: FPF-1070

**Mechanism of Action** Cerebrolysin (FPF-1070) is a porcine brain-derived peptide preparation composed of low-molecular-weight neuropeptides and amino acids. It mimics the actions of endogenous neurotrophic factors, such as nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF), by binding to their receptors and activating downstream signaling pathways (e.g., Trk and MAPK/ERK). This promotes neuronal survival, synaptic plasticity, and neurogenesis, while reducing excitotoxicity, oxidative stress, and neuroinflammation. Its multimodal effects are attributed to the synergistic activity of its peptide fragments rather than a single molecular target. **Key Research Findings** Clinical trials have demonstrated Cerebrolysin’s efficacy in improving functional outcomes in acute ischemic stroke, particularly when administered within 24–72 hours of onset, with meta-analyses showing enhanced neurological recovery and reduced disability. In traumatic brain injury (TBI), studies report accelerated cognitive and motor recovery, though results are less consistent. For dementia, including Alzheimer’s disease, Cerebrolysin has shown modest benefits in cognition and global function in short-term trials (e.g., 4–24 weeks), but long-term data remain limited. Adverse effects are generally mild (e.g., dizziness, injection-site reactions), and no significant safety concerns have emerged in controlled studies. **Clinical Relevance** Cerebrolysin is approved in over 40 countries for stroke, TBI, and dementia, but not by the FDA for use in the United States. Its clinical utility is supported by moderate-quality evidence for acute stroke and dementia, though heterogeneity in trial designs and outcome measures limits definitive conclusions. Ongoing research aims to optimize dosing, identify responsive patient subgroups, and evaluate combination therapies. For research purposes only — not medical advice.

Key data

Research & studies

Frequently asked questions

Related peptides